Assessing biomarkers for early detection and monitoring of X-linked dystonia parkinsonism
Clinical trial readiness in X-linked dystonia parkinsonism: assessment of sensor-based and blood biomarkers for early detection and monitoring disease progression
This study is looking at how special sensors and blood tests can help find and track the early signs of X-linked dystonia parkinsonism (XDP), a rare movement disorder, so that patients can get better care and treatment over time.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10912566 on NIH RePORTER |
What this research studies
This research investigates how sensor-based and blood biomarkers can be used to detect and monitor the progression of X-linked dystonia parkinsonism (XDP), a rare neurogenetic movement disorder. By utilizing motion sensors and biochemical analysis, the study aims to identify early signs of the disease that may not yet be visible through traditional clinical assessments. The project will also employ machine learning techniques to optimize the evaluation of these biomarkers, providing a more reliable method for tracking disease severity over time. This approach could lead to improved clinical trial endpoints and better patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with X-linked dystonia parkinsonism or those who are carriers of the genetic mutation associated with the disorder.
Not a fit: Patients with movement disorders unrelated to X-linked dystonia parkinsonism may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier diagnosis and more effective monitoring of X-linked dystonia parkinsonism, ultimately improving treatment strategies for patients.
How similar studies have performed: Previous research has shown promise in using biomarkers and sensor technology for monitoring other movement disorders, suggesting that this approach may also be effective for XDP.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Stephen, Christopher D — Massachusetts General Hospital
- Study coordinator: Stephen, Christopher D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.